Anixa Biosciences, Inc. (ANIX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE, CA 95118
State of Incorp. DE
Fiscal Year End October 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

7/31/2023
Q3
4/30/2023
Q2
1/31/2023
Q1
10/31/2022
Q4
7/31/2022
Q3
4/30/2022
Q2
1/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments26,97627,70229,68731,66432,23134,530
Cash and cash equivalents5,6209,79012,36024,25427,73229,781
Short-term investments21,35617,91217,3277,4104,4994,749
Receivables256147    
Other undisclosed current assets178256513676332464
Total current assets:27,41028,10530,20032,34032,56334,994
Noncurrent Assets
Operating lease, right-of-use asset189201212223234244
Total noncurrent assets:189201212223234244
TOTAL ASSETS:27,59928,30630,41232,56332,79735,238
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,4881,1851,9911,4251,1501,746
Accounts payable19511026522793504
Accrued liabilities1,2931,0751,7261,1981,0571,242
Other undisclosed current liabilities494746443941
Total current liabilities:1,5371,2322,0371,4691,1891,787
Noncurrent Liabilities
Long-term debt and lease obligation:    187202209
Liabilities, other than long-term debt149162175   
Operating lease, liability149162175187202209
Other undisclosed noncurrent liabilities    (187)(202)(209)
Total noncurrent liabilities:149162175187202209
Total liabilities:1,6861,3942,2121,6561,3911,996
Equity
Equity, attributable to parent26,81127,79129,04731,70132,17133,963
Common stock310309309307302301
Additional paid in capital249,496248,189247,123246,303244,032242,281
Accumulated deficit(222,995)(220,707)(218,385)(214,909)(212,163)(208,619)
Equity, attributable to noncontrolling interest(898)(879)(847)(794)(765)(721)
Total equity:25,91326,91228,20030,90731,40633,242
TOTAL LIABILITIES AND EQUITY:27,59928,30630,41232,56332,79735,238

Income Statement (P&L) ($ in thousands)

7/31/2023
Q3
4/30/2023
Q2
1/31/2023
Q1
10/31/2022
Q4
7/31/2022
Q3
4/30/2022
Q2
1/31/2022
Q1
Revenues 210    513
Cost of revenue(1,159)(1,068)(6,477)(86)(1,735)(1,838)
Gross profit:(949)(1,068)(6,477)(86)(1,735)(1,325)
Operating expenses(1,611)(1,488)2,868(2,711)(1,854)(2,042)
Other undisclosed operating loss      (513)
Operating loss:(2,560)(2,556)(3,609)(2,797)(3,589)(3,880)
Loss from continuing operations:(2,560)(2,556)(3,609)(2,797)(3,589)(3,880)
Loss before gain (loss) on sale of properties:(2,797)(3,589)(3,880)
Other undisclosed net income253202802211
Net loss:(2,307)(2,354)(3,529)(2,775)(3,588)(3,879)
Net income attributable to noncontrolling interest193253294450
Net loss available to common stockholders, diluted:(2,288)(2,322)(3,476)(2,746)(3,544)(3,829)

Comprehensive Income ($ in thousands)

7/31/2023
Q3
4/30/2023
Q2
1/31/2023
Q1
10/31/2022
Q4
7/31/2022
Q3
4/30/2022
Q2
1/31/2022
Q1
Net loss:(2,307)(2,354)(3,529)(2,775)(3,588)(3,879)
Comprehensive loss:(2,307)(2,354)(3,529)(2,775)(3,588)(3,879)
Comprehensive income, net of tax, attributable to noncontrolling interest193253294450
Comprehensive loss, net of tax, attributable to parent:(2,288)(2,322)(3,476)(2,746)(3,544)(3,829)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: